Literature DB >> 1592887

Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone.

A Le Quellec1, A Kervran, P Blache, A J Ciurana, D Bataille.   

Abstract

The biological specificity of oxyntomodulin toward the gastric mucosa results from its C-terminal octapeptide. A RIA using a specific antibody raised against this region permitted quantification of the whole set of proglucagon-derived peptides that interact with the oxyntomodulin recognition systems, corresponding to the new concept of oxyntomodulin-like-immunoreactivity (OLI). The present report describes the physiological 24-h OLI profile in human plasma (eight men and eight women; mean age, 45 yr; range, 20-77 yr). Blood was withdrawn every hour from 0700-1900 h and every 2 h from 2100-0500 h. A meal-dependent profile was found for circulating OLI, with basal values (60 +/- 7 ng/L) at 0500 h and rises elicited by each food intake. The highest value (136 +/- 21 ng/L) was obtained at 2100 h. Plasma concentrations and diurnal variations of OLI were similar to those of the other intestinal peptides known to exert an endocrine function. The mean circulating OLI values increased with age, whereas no change was noticed according to sex. The inhibitory effect exerted by the peptides of the OLI family on gastric acid secretion, the meal dependence of their plasma concentrations, and the observed synchronism of their diurnal profile with that previously described for somatostatin make them candidates for an enterogastrone action.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592887     DOI: 10.1210/jcem.74.6.1592887

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes.

Authors:  Blandine Laferrère; Nicholas Swerdlow; Baani Bawa; Sara Arias; Mousumi Bose; Blanca Oliván; Julio Teixeira; James McGinty; Kristina I Rother
Journal:  J Clin Endocrinol Metab       Date:  2010-05-25       Impact factor: 5.958

Review 2.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 4.  Gastrointestinal hormones regulating appetite.

Authors:  Owais Chaudhri; Caroline Small; Steve Bloom
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

5.  Oxyntomodulin reduces hydromineral transport through rat small intestine.

Authors:  F Beauclair; B Eto; D Pansu; G Rodier; T Mochizuki; J Martinez; D Bataille; C Jarrousse
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 6.  Treatment of Obesity in Mitigating Metabolic Risk.

Authors:  Sean P Heffron; Johnathon S Parham; Jay Pendse; José O Alemán
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 7.  Pro-protein convertases in intermediary metabolism: islet hormones, brain/gut hormones and integrated physiology.

Authors:  Dominique Bataille
Journal:  J Mol Med (Berl)       Date:  2007-03-14       Impact factor: 4.599

Review 8.  Recent developments in the pathophysiology of irritable bowel syndrome.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 9.  Unraveling oxyntomodulin, GLP1's enigmatic brother.

Authors:  Alessandro Pocai
Journal:  J Endocrinol       Date:  2012-09-27       Impact factor: 4.286

Review 10.  Diet in irritable bowel syndrome.

Authors:  Magdy El-Salhy; Doris Gundersen
Journal:  Nutr J       Date:  2015-04-14       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.